Rhinomed (ASX:RNO) Total Liabilities : A$9.48 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Total Liabilities?

Rhinomed's Total Liabilities for the quarter that ended in Jun. 2023 was A$9.48 Mil.

Rhinomed's quarterly Total Liabilities increased from Jun. 2022 (A$3.46 Mil) to Dec. 2022 (A$9.05 Mil) and increased from Dec. 2022 (A$9.05 Mil) to Jun. 2023 (A$9.48 Mil).

Rhinomed's annual Total Liabilities increased from Jun. 2021 (A$1.78 Mil) to Jun. 2022 (A$3.46 Mil) and increased from Jun. 2022 (A$3.46 Mil) to Jun. 2023 (A$9.48 Mil).

Rhinomed Total Liabilities Historical Data

The historical data trend for Rhinomed's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Total Liabilities Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

1.25

1.96

1.78

3.46

9.48

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															1.78	3.27	3.46	9.05	9.48

Rhinomed Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Rhinomed's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.381	+	(0.015	+	-3.6082248300318E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.085)
	=	9.48

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	3.075	-	-6.406
	=	9.48

Rhinomed's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.381	+	(0.015	+	-3.6082248300318E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.085)
	=	9.48

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	3.075	-	-6.406
	=	9.48

Rhinomed Total Liabilities Related Terms

Thank you for viewing the detailed overview of Rhinomed's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines